0000000001158003

AUTHOR

Giulia Culletta

showing 13 related works from this author

Investigating the inhibition of FTSJ1 a tryptophan tRNA-specific 2’-O-methyltransferase by NV TRIDs, as a mechanism of readthrough in nonsense mutate…

2023

Abstract: Cystic Fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the CFTR gene, coding for the CFTR chloride channel. About 10% of the CFTR gene mutations are "stop" mutations, which generate a Premature Termination Codon (PTC), thus synthesizing a truncated CFTR protein. A way to bypass PTC relies on ribosome readthrough, which is the ri-bosome’s capacity to skip a PTC, thus generating a full-length protein. “TRIDs” are molecules exerting ribosome readthrough; for some, the mechanism of action is still under debate. We in-vestigate a possible mechanism of action (MOA) by which our recently synthesized TRIDs, namely NV848, NV914, and NV930, could exert their r…

Settore BIO/18 - GeneticaKeywords: FTSJ1 methyltransferase tRNA readthrough stop codon mutation small molecules docking molecular dynamics MM-GBSASettore CHIM/06 - Chimica OrganicaSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Evaluation of the IKKβ Binding of Indicaxanthin by Induced-Fit Docking, Binding Pose Metadynamics, and Molecular Dynamics

2021

Background: Indicaxanthin, a betaxanthin belonging to the betalain class of compounds, has been recently demonstrated to exert significant antiproliferative effects inducing apoptosis of human melanoma cells through the inhibition of NF-κB as the predominant pathway. Specifically, Indicaxanthin inhibited IκBα degradation in A375 cells. In resting cells, NF-κB is arrested in the cytoplasm by binding to its inhibitor protein IκBα. Upon stimulation, IκBα is phosphorylated by the IKK complex, and degraded by the proteasome, liberating free NF-κB into the nucleus to initiate target gene transcription. Inhibition of the IKK complex leads to the arrest of the NF-κB pathway.Methods: To acquire deta…

PharmacologyMolecular modelChemistryAllosteric regulationIKKβMetadynamicsindicaxanthinInhibitor proteinRM1-950Settore CHIM/08 - Chimica Farmaceuticamolecular dynamicsIκBαchemistry.chemical_compoundanticancer activityProteasomeDocking (molecular)Settore BIO/10 - BiochimicaBiophysicsbinding pose metadynamicsPharmacology (medical)induced fit dockingTherapeutics. PharmacologyIndicaxanthinOriginal ResearchFrontiers in Pharmacology
researchProduct

A Definitive Pharmacophore Modelling Study on CDK2 ATP Pocket Binders: Tracing the Path of New Virtual High-Throughput Screenings

2020

Cyclin Dependent Kinases-2 (CDK2) are members of serine/threonine protein kinases family. They play an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidence indicate that excessive expression of CDK2s should cause abnormal cell cycle regulation. Therefore, since a long time, CDK2s have been considered potential therapeutic targets for cancer therapy. In this work, onehundred and forty-nine complexes of inhibitors bound in the CDK2-ATP pocket were submitted to short MD simulations (10ns) and free energy calculation. Comparison with experimental data (K<sub>i</sub>, K<sub>d</su…

CDK20301 basic medicineComputer scienceATP pocketCancer therapyComputational biologyMolecular dynamicsTracingCommon hits approachInhibitory Concentration 5003 medical and health sciencesMolecular dynamicsAdenosine Triphosphate0302 clinical medicineNeoplasmsDrug DiscoveryHumansProtein Kinase InhibitorsThroughput (business)Eukaryotic cellMM-GBSABinding SitesbiologyCyclin-Dependent Kinase 2Cyclin-dependent kinase 2High-Throughput Screening AssaysMolecular Docking Simulation030104 developmental biology030220 oncology & carcinogenesisPharmacophore modellingPath (graph theory)biology.proteinPharmacophoreProtein BindingCurrent Drug Discovery Technologies
researchProduct

Uno studio comparativo in silico sui possibili target di Ataluren e analoghi farmaci promotori di readthrough di codoni di stop prematuri

2019

E’ noto in letteratura che Ataluren (acido 5-(fluorofenil)-1,2,4-ossadiazolil-benzoico) sia in grado di sopprimere le mutazioni non senso favorendo il readthrough dei codoni di stop prematuri, anche se il suo meccanismo di azione non risulta ancora chiaro. La probabile interazione tra Ataluren e CTFR-mRNA è stata precedentemente studiata mediante dinamica molecolare. In questo studio1, abbiamo esteso il modeling del probabile meccanismo di azione di Ataluren mediante approcci computazionali completementari, quali Induced Fit Docking (IFD), Quantum Polarized Ligand Docking (QPLD), metodi MM-GBSA e mutagenesi computazionale. Oltre a considerare il CTFR-mRNA, sono stati presi in considerazione…

in silico readthrough CFTR Fibrosi cistica Ataluren
researchProduct

Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs)

2020

[Image: see text] Translational readthrough-inducing drugs (TRIDs) rescue the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs). Small molecules have been developed as TRIDs to trick the ribosomal machinery during recognition of the PTC. Herein we report a computational study to identify new TRID scaffolds. A pharmacophore approach was carried out on compounds that showed readthrough activity. The pharmacophore model applied to screen different libraries containing more than 87000 compounds identified four hit-compounds presenting scaffolds with diversity from the oxadiazole lead. These compounds have been s…

010405 organic chemistryChemistryOrganic ChemistryTranslational readthroughNonsense mutationHTVSnonsense mutationOxadiazoleBenzoxazoleRibosomal RNA01 natural sciencesBiochemistrySmall molecule0104 chemical sciencescystic fibrosis010404 medicinal & biomolecular chemistrychemistry.chemical_compoundBiochemistryDrug Discoverypremature termination codonsPharmacophoreDerivative (chemistry)Pharmacophore modeling
researchProduct

Exploring the SARS-CoV-2 Proteome in the Search of Potential Inhibitors via Structure-based Pharmacophore Modeling/Docking Approach

2020

To date, SARS-CoV-2 infectious disease, named COVID-19 by the World Health Organization (WHO) in February 2020, has caused millions of infections and hundreds of thousands of deaths. Despite the scientific community efforts, there are currently no approved therapies for treating this coronavirus infection. The process of new drug development is expensive and time-consuming, so that drug repurposing may be the ideal solution to fight the pandemic. In this paper, we selected the proteins encoded by SARS-CoV-2 and using homology modeling we identified the high-quality model of proteins. A structure-based pharmacophore modeling study was performed to identify the pharmacophore features for each…

General Computer ScienceComputer scienceComputational biologylcsh:QA75.5-76.95Theoretical Computer Science03 medical and health sciences0302 clinical medicineHomology modelingMM-GBSA030304 developmental biology0303 health sciencesVirtual screeningpharmacophoreSARS-CoV-2Applied MathematicsCOVID-19computational chemistryCOVID-19 SARS-CoV-2 computational chemistry structure-based pharmacophore docking MM-GBSADrug repositioningstructure-basedDrug developmentInfectious disease (medical specialty)Docking (molecular)030220 oncology & carcinogenesisModeling and Simulationdockinglcsh:Electronic computers. Computer sciencePharmacophoreDrugBankComputation
researchProduct

Comparing molecular dynamics-derived pharmacophore models with docking: A study on CDK-2 inhibitors

2020

Abstract We compared the performance of molecular dynamics (MD)-derived pharmacophore modeling approaches, Common Hit Approach (CHA), and the Molecular dYnamics SHAred PharmacophorE (MYSHAPE) approach, with semi-flexible constrained/unconstrained docking. The aim of this work is to enrich the hit-list of a virtual screening on CDK-2 known inhibitors as a case study. Cyclin-dependent kinases (CDKs) deregulation is associated with cancer growth. CDKs are an attractive target for anticancer agents. MD-derived pharmacophore models have been obtained with LigandScout 4.2.1. Docking analysis has been performed through Glide 7.6. The results highlighted the MYSHAPE approach has a better performanc…

CDK2Virtual screeningbiologyPharmacophore010405 organic chemistryChemistryGeneral ChemistryComputational biologyMolecular dynamics010402 general chemistry01 natural sciencesDynamic pharmacophoreLigandScout0104 chemical sciencesDockingMolecular dynamicsCyclin-dependent kinaseDocking (molecular)biology.proteinPharmacophore
researchProduct

Immunoproteasome and Non-Covalent Inhibition: Exploration by Advanced Molecular Dynamics and Docking Methods

2021

The selective inhibition of immunoproteasome is a valuable strategy to treat autoimmune, inflammatory diseases, and hematologic malignancies. Recently, a new series of amide derivatives as non-covalent inhibitors of the β1i subunit with Ki values in the low/submicromolar ranges have been identified. Here, we investigated the binding mechanism of the most potent and selective inhibitor, N-benzyl-2-(2-oxopyridin-1(2H)-yl)propanamide (1), to elucidate the steps from the ligand entrance into the binding pocket to the ligand-induced conformational changes. We carried out a total of 400 ns of MD-binding analyses, followed by 200 ns of plain MD. The trajectories clustering allowed identifying thre…

Proteasome Endopeptidase ComplexStereochemistryPharmaceutical ScienceOrganic chemistryinduced-fit dockingMolecular Dynamics Simulation01 natural sciencesArticlemetadynamicsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compoundimmunoproteasomeQD241-441AmideDrug DiscoveryOrganosilicon CompoundsPhysical and Theoretical Chemistrynon-covalent inhibitor030304 developmental biology0303 health sciencesBinding Sites010405 organic chemistrymolecular dynamicnon-covalent inhibitorsMetadynamicsRational designDipeptidesLigand (biochemistry)PropanamideSettore CHIM/08 - Chimica Farmaceuticamolecular dynamics0104 chemical sciencesMolecular Docking SimulationchemistryChemistry (miscellaneous)Docking (molecular)MD bindingMolecular MedicinemetadynamicLead compoundOligopeptidesProteasome InhibitorsAcetamideProtein BindingMolecules
researchProduct

Indicaxanthin, a multi-target natural compound from Opuntia ficus-indica fruit: From its poly-pharmacological effects to biochemical mechanisms and m…

2019

Abstract Over the latest years phytochemical consumption has been associated to a decreased risk of both the onset and the development of a number of pathological conditions. In this context indicaxanthin, a betalain pigment from Opuntia ficus-indica fruit, has been the object of sound research. Explored, at first, for its mere antioxidant potential, Indicaxanthin is now regarded as a redox-active compound able to exert significant poly-pharmacological effects against several targets in a number of experimental conditions both in vivo and in vitro. This paper aims to provide an overview on the therapeutical effects of indicaxanthin, ranging from the anti-inflammatory to the neuro-modulatory…

Models MolecularPyridinesOpuntia ficusPhytochemicalsContext (language use)Antioxidant potential01 natural sciencesMiceStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundMulti targetCell Line TumorNeoplasmsSettore BIO/10 - BiochimicaBetalainDrug DiscoveryAnimalsHumansCell Proliferation030304 developmental biologyInflammationIndicaxanthin Multi-target compound Poly-pharmacology Antioxidant Antiinflammatory Antitumoral Antiproliferative Neuromodulator Molecular modellingPharmacologyBiological Products0303 health sciencesDose-Response Relationship DrugMolecular StructureTraditional medicine010405 organic chemistryNatural compoundOrganic ChemistryOpuntiaGeneral MedicineAntineoplastic Agents PhytogenicSettore CHIM/08 - Chimica FarmaceuticaBetaxanthins0104 chemical sciencesMice Inbred C57BLNeuroprotective AgentsPhytochemicalchemistryBlood-Brain BarrierFruitDrug Screening Assays AntitumorIndicaxanthinEuropean Journal of Medicinal Chemistry
researchProduct

Fighting Antibiotic Resistance: New Pyrimidine-Clubbed Benzimidazole Derivatives as Potential DHFR Inhibitors

2023

The present work describes the design and development of seventeen pyrimidine-clubbed benzimidazole derivatives as potential dihydrofolate reductase (DHFR) inhibitors. These compounds were filtered by using ADMET, drug-likeness characteristics calculations, and molecular docking experiments. Compounds 27, 29, 30, 33, 37, 38, and 41 were chosen for the synthesis based on the results of the in silico screening. Each of the synthesized compounds was tested for its in vitro antibacterial and antifungal activities using a variety of strains. All the compounds showed antibacterial properties against Gram-positive bacteria (Staphylococcus aureus and Staphylococcus pyogenes) as well as Gram-negativ…

pyrimidineADMETlab 2.0Organic ChemistryPharmaceutical Sciencemolecular dockingDHFRSettore CHIM/08 - Chimica FarmaceuticabenzimidazoleAnalytical ChemistryDHFR; antifungal; antibacterial; pyrimidines; benzimidazoles; ADMETlab 2.0; molecular dockingantibacterialChemistry (miscellaneous)Drug DiscoveryMolecular MedicinePhysical and Theoretical ChemistryantifungalMolecules; Volume 28; Issue 2; Pages: 501
researchProduct

In Silico Design, Synthesis and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity

2022

Telomerase, a reverse transcriptase enzyme involved in DNA synthesis, has a tangible role in tumor progression. Several studies have evidenced telomerase as a promising target for developing cancer therapeutics. The main reason is due to the overexpression of telomerase in cancer cells (85–90%) compared with normal cells where it is almost unexpressed. In this paper, we used a structure-based approach to design potential inhibitors of the telomerase active site. The MYSHAPE (Molecular dYnamics SHared PharmacophorE) approach and docking were used to screen an in-house library of 126 arylsulfonamide derivatives. Promising compounds were synthesized using classical and green methods. Com…

SulfonamidesRPharmaceutical ScienceAnticancer compounds; Arylsulfonamide; Docking; Molecular dynamics; Pharmacophore modeling; Structure-based drug design; Sulfonamides; Telomerase inhibitorsMolecular dynamicsSettore CHIM/08 - Chimica FarmaceuticaArticleDockingRS1-441Anticancer compoundsTelomerase inhibitorsPharmacy and materia medicaDrug DiscoveryArylsulfonamideMedicineMolecular Medicinesulfonamides; arylsulfonamide; anticancer compounds; telomerase inhibitors; structure-based drug design; pharmacophore modeling; docking; molecular dynamicsStructure-based drug designPharmacophore modeling
researchProduct

CHA on CDK2: a way to identify the best pharmacophore model for the virtual screening of new inhibitors

2018

Cyclin-dependent kinase-2 (CDK2) is a member of serine/threonine protein kinases family. It plays an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidences indicate that excessive expression of CDK2 should cause abnormal cell cycle regulation. Therefore, CDK2 has been considered a potential therapeutic target for cancer therapy. In this work, we used a modelling approach that incorporates flexibility based on extensive MD simulations of protein−ligand complexes into structure-based pharmacophore modeling and virtual screening to identify new CDK2 inhibitors. One-hundred and forty-nine CDK2-inhibit…

cdk2 pharmacophore modelling virtual screening
researchProduct

Sulfonamide moiety as "molecular chimera" in the design of new drugs.

2021

Background: The -SO2NH- group is of great significance in modern pharmaceutical use since, in sulfa-drugs, it is possible to introduce easily chemical modifications, and even small changes may lead to an improved version of an already existing drug. Objective: This paper aims to describe updated information in the sulfonamide field with a particular focus on new mechanisms of action, especially if discovered by employing computational approaches. Methods: Research articles that focused on the use of the sulfonamide moiety for the design, synthesis, and in vitro/in vivo tests of various diseases were collected from various search engines like PubMed, Science Direct, Google Scholar, and Scop…

sulfonamide moietyPharmacologyOrganic Chemistrymolecular chimeraSettore CHIM/08 - Chimica FarmaceuticaBiochemistrymolecular dynamicsin silico drug designdockingDrug Discoverypharmacophore modelingMolecular Medicinealkylsulfonamidesaryl/heteroarylsulfonamidesCurrent medicinal chemistry
researchProduct